views: 1797
Readers community rating: votes 0
1. Scapini P., Marini O., Tecchio C., Cassatella M. A. Human neutrophils in the saga of cellular heterogeneity: insights and open questions. Immunol. Rev. 2016, 273(1) 48–60. DOI: 10.1111/imr.12448.
2. Kobayashi Y. Neutrophil biology: an update. EXCLI J. 2015, 14, 220–227. DOI: 10.17179/excli2015–102.
3. Nesterova I. V., Kolesnikova N. V., Chudilova G. A., Lomtatidze L. V., Kovaleva S. V., Evglevskij A. A., Nguen T. Z.L. Novyj vzglyad na nejtrofil'nye granulotsity: pereosmyslenie starykh dogm. (Chast' 1). Infektsiya i Immunitet 2017, 7(3), 219– 230. DOI:10.15789/2220–7619–2017–3–219–230. [Nesterova I. V., Kolesnikova N. V., Chudilova G. A., Lomtatidze L. V., Kovaleva S. V., Yevglevsky A. A., Nguyen T. Z.L. A new look at neutrophilic granulocytes: rethinking old dogmas. (Part 1). Infection and immunity 2017, 7(3), 219–230. DOI:10.15789/2220–7619–2017–3–219–230. Russian].
4. Garley M., Jablonska E. Heterogeneity among neutrophils. Arch. Immunol. Ther. Exp. (Warsz). 2018, 66(1), 21–30. DOI: 10.1007/s00005–017–0476–4.
5. Nesterova I. V., Kolesnikova N. V., Chudilova G. A., Lomtatidze L. V., Kovaleva S. V., Evglevskij A. A., Nguen T. Z.L. Novyj vzglyad na nejtrofil'nye granulotsity: pereosmyslenie starykh dogm. (Chast' 2). Infektsiya i immunitet 2018, 8(1), 7–18. DOI: 10.15789/2220–7619–2018–1–7–18. [Nesterova I. V., Kolesnikova N. V., Chudilova G. A., Lomtatidze L. V., Kovaleva S. V., Yevglevsky A. A., Nguyen T. Z.L. A new look at neutrophilic granulocytes: rethinking old dogmas. (Part 2). Infection and immunity 2017, 7(3), 219–230. DOI: 10.15789/2220–7619–2018–1–7–18. Russian].
6. Elghetany M. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol. Dis. 2002, 28 (2): 260–274. PMID12064921.
7. Garnache-Ottou F., Chaperot L., Biichle S., Ferrand C., Remy-Martin J. P., Deconinck E., de Tailly P. D., Bulabois B., Poulet J., Kuhlein E., Jacob M. C., Salaun V., Arock M., Drenou B., Schillinger F., Seilles E., Tiberghien P., Bensa J. C., Plumas J., Saas P. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood 2005, 105(3), 1256–1264. DOI: 10.1182/blood-2004–06–2416.
8. Hernandez-Caselles T., Martinez-Esparza M., Perez-Oliva A. B., Quintanilla-Cecconi A. M., Garcia-Alonso A., Alvarez-Lopez D. M., Garcia-Penarrubia P. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. Journal of Leukocyte Biology 2006, 79(1), 46–58. DOI: 10.1189/jlb.0205096.
9. Crocker P. R., Zhang J. New I-type lectins of the CD33- related siglec subgroup identifi ed through genomics. Biochemical Society Symposia 2002, 69; 83–94. DOI: 10.1042/bss0690083.
10. Bandura D. R., Baranov V. I., Ornatsky O. I., Antonov A., Kinach R., Udong Lou X., Pavlov S., Vorobiev S., Dick J. E. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-fl ight mass spectrometry. Analytical Chemistry 2009, 81, 6813–6822. DOI: 10.1021/ac901049w.
11. Ornatsky O., Bandura D., Baranov V., Nitz M., Winnik M. A., Tanner S. Highly multiparametric analysis by mass cytometry. J. Immunol. Methods 2010, 361(1–2), 1–20. DOI: 10.1016/j.jim.2010.07.002.
12. Schroder A. K., Uciechowski P., Fleischer D., Rink L. Crosslinking of CD66b on peripheral blood neutrophils mediates the release of interleukin-8 from intracellular storage. Hum. Immunol. 2006, 67(9), 676–682. DOI: 10.1016/j.humimm.2006.05.004.
13. Mandruzzato S., Brandau S., Britten C. M., Bronte V., Damuzzo V., Gouttefangeas C., Maurer D., Ottensmeier C., van der Burg S. H., Welters M. J., Walter S. Toward harmonized phenotyping of human myeloidderived suppressor cells by fl ow cytometry: results from an interim study. Cancer Immunol. Immunother. 2016, 65(2), 161–169. DOI: 10.1007/s00262–015–1782–5.
14. Zhang Y., Boesen C. C., Radaev S., Brooks A. G., Fridman W. H., Sautes-Fridman C., Sun P. D. Crystal structure of the extracellular domain of a human Fc?RIII”. Immunity. 2000, 13 (3), 387–95. DOI:10.1016/S1074–7613(00)00038–8.
15. Nesterova I. V. Preparaty interferona al'fa v klinicheskoj praktike: kogda i kak. Lechaschij vrach 2017, 9, 66–76. https://www.lvrach.ru/2017/9/ [Nesterova I. V. Interferon alfa preparations in clinical practice: when and how. Treatment doctor 2017, 9, 66–76. https://www.lvrach.ru/2017/9/. Russian].
16. Brandacher G., Margreiter D., Fuchs D. Implications of IFN-gamma-mediated tryptophan catabolism on solid organ transplantation. Curr. Drug Metab. 2007, 8(3), 273–282. PMID: 17430115.
17. Sato T., Hongu T., Sakamoto M., Funakoshi Y., Kanaho Y. Molecular mechanisms of N-Formyl-Methionylleucyl- phenylalanine-induced superoxide generation and degranulation in mouse neutrophils: phospholipase D is dispensable. Mol. Cell Biol. 2013, 33(1), 136–145. DOI: 10.1128/MCB.00869–12.
18. Schmidt T., Brodesser A., Schnitzler N., Gruger T., Brandenburg K., Zinserling J., Zundorf J. CD66b overexpression and loss of C5a receptors as surface markers for Staphylococcus aureus-induced neutrophil dysfunction. PLoS ONE2015, 10(7), e0132703. DOI: 10.1371/journal.pone.0132703.